ArticleMucosal immunology2018
Herpes simplex virus-binding IgG traps HSV in human cervicovaginal mucus across the menstrual cycle and diverse vaginal microbial composition.
Article in Mucosal immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 36 citations in OpenAlex.
- Beyond the Barrier: Epithelial Cells as Immune Sentinels in the Female Genital Tract.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
- Engineering Decavalent, Sperm-Binding Laminin-IgG Hybrid Antibodies for Potent Non-Hormonal Contraception.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Vaginally-delivered fast-dissolving antibody tablets (FDAT) for on-demand non-hormonal contraception and multi-purpose protection.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Leveraging the microbiome to combat antibiotic resistant gynecological infections.npj antimicrobials and resistance · 2025Review
- Sulfated Cellulose Nanofiber Hydrogel with Mucus-Like Activities for Virus Inhibition.ACS applied materials & interfaces · 2024Article
- ZMapp reduces diffusion of Ebola viral particles in fresh human cervicovaginal mucus.Emerging microbes & infections · 2024Article
- Engineering a "muco-trapping" ACE2-immunoglobulin hybrid with picomolar affinity as an inhaled, pan-variant immunotherapy for COVID-19.Bioengineering & translational medicine · 2024Article
- Inhaled "Muco-Trapping" Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Different Forms of TFF3 in the Human Endocervix, including a Complex with IgG Fc Binding Protein (FCGBP), and Further Aspects of the Cervico-Vaginal Innate Immune Barrier.International journal of molecular sciences · 2024Article
- Broadly neutralizing antibodies consistently trap HIV-1 in fresh cervicovaginal mucus from select individuals.Acta biomaterialia · 2023Article
- Review
- Synthetic Mucin Gels with Self-Healing Properties Augment Lubricity and Inhibit HIV-1 and HSV-2 Transmission.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Passive immunization of the human vagina.Human vaccines & immunotherapeutics · 2022Article
- The biophysical principles underpinning muco-trapping functions of antibodies.Human vaccines & immunotherapeutics · 2022Review
- Insight into the ecology of vaginal bacteria through integrative analyses of metagenomic and metatranscriptomic data.Genome biology · 2022Article
- Monoclonal antibody therapy of herpes simplex virus: An opportunity to decrease congenital and perinatal infections.Frontiers in immunology · 2022Review
- Hexavalent sperm-binding IgG antibody released from vaginal film for development of potent on-demand nonhormonal female contraception.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Semen: A modulator of female genital tract inflammation and a vector for HIV-1 transmission.American journal of reproductive immunology (New York, N.Y. : 1989) · 2021Review
- Protection and Risk: Male and Female Genital Microbiota and Sexually Transmitted Infections.The Journal of infectious diseases · 2021Review
- Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.Advanced drug delivery reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
IgG possesses an important yet little recognized effector function in mucus. IgG bound to viral surface can immobilize otherwise readily diffusive viruses to the mucin matrix, excluding them from contacting target cells and facilitating their elimination by natural mucus clearance mechanisms. Cervicovaginal mucus (CVM) is populated by a microbial community, and its viscoelastic and barrier properties can vary substantially not only across the menstrual cycle, but also in women with distinct microbiota. How these variations impact the "muco-trapping" effector function of IgGs remains poorly understood. Here we obtained multiple fresh, undiluted CVM specimens (n = 82 unique specimens) from six women over time, and employed high-resolution multiple particle tracking to quantify the mobility of fluorescent Herpes Simplex Viruses (HSV-1) in CVM treated with different HSV-1-binding IgG. The IgG trapping potency was then correlated to the menstrual cycle, and the vaginal microbial composition was determined by 16 s rRNA. In the specimens studied, both polyclonal and monoclonal HSV-1-binding IgG appeared to consistently and effectively trap HSV-1 in CVM obtained at different times of the menstrual cycle and containing a diverse spectrum of commensals, including G. vaginalis-dominant microbiota. Our findings underscore the potential broad utility of this "muco-trapping" effector function of IgG to reinforce the vaginal mucosal defense, and motivates further investigation of passive immunization of the vagina as a strategy to protect against vaginally transmitted infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.